

Contents lists available at ScienceDirect

Journal of Medical Mycology



journal homepage: www.elsevier.com

General review

COVID-19-associated mixed mold infection: A case report of aspergillosis and mucormycosis and a literature review



Yasmine Benhadid-Brahmi^a, Samia Hamane^a, Benjamin Soyer^{b,c,d}, Alexandre Mebazaa^{b,c,d}, Alexandre Alanio^{a,e}, Benjamin Chousterman^{b,c,d}, Stéphane Bretagne^{a,e}, Sarah Dellière^{a,e,*}

^a Université de Paris, Laboratoire de Parasitologie-Mycologie, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand-Widal, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

^b Université de Paris, FHU Promice, Département d'anesthésie-réanimation, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand-Widal, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

^c INI-CRCT Network. Nancy. France

^d INSERM U942, Paris, France

^e Institut Desteur Université de

^e Institut Pasteur, Université de Paris, CNRS UMR2000, unité de Mycologie Moléculaire, Centre national de Référence Mycoses Invasives et Antifongiques, F-75015 Paris, France

ARTICLE INFO

Article History: Received 22 May 2021 Revised 2 November 2021 Accepted 25 November 2021 Available online 26 November 2021

Keywords: Aspergillosis COVID-19 Mucormycosis SARS-CoV-2 Invasive fungal disease Corticosteroids

Introduction

ABSTRACT

COVID-19-associated mold infections have been increasingly reported, and the main entity is COVID-19associated aspergillosis (CAPA). Similarly, COVID-19-associated mucormycosis has been reported in hematology, and its prevalence is high and has been increasing in the diabetic population in India during the third COVID-19 pandemic wave. Simultaneous infection with Mucorales and *Aspergillus* is rare and even rarer during COVID-19. Here, we report the case of a previously immunocompetent patient with severe SARS-CoV-2 infection complicated with probable CAPA and mucormycosis co-infection. Specific diagnostic tools for mucormycosis are lacking, and this case highlights the advantages of analyzing blood and respiratory samples using the quantitative polymerase chain reaction to detect these fungi. We further reviewed the literature on mixed *Aspergillus*/Mucorales invasive fungal diseases to provide an overview of patients presenting with both fungi and to identify characteristics of this rare infection.

© 2021 SFMM. Published by Elsevier Masson SAS. All rights reserved.

Aspergillus coinfection in a previously immunocompetent COVID-19 patient and a discussion about mixed mold infections.

CASE

A 74-year-old retired man with a history of hypertension that was being treated with calcium channel blockers presented in the emergency ward on October 21, 2020 with a cough and a fever that lasted 4 days (Figure 1). He had evocative chest computed tomography (CT) scan findings, and the COVID-19 diagnosis was confirmed using real-time reverse-transcriptase polymerase chain reaction (PCR) on a nasopharyngeal swab (RealStar[®] SARS-CoV-2 Kit, Altona Diagnostics). The patient had a history of gastric lymphoma that was treated surgically in 1975, and he has subsequently been in remission.

Upon admission in the pneumology ward, the patient received ceftriaxone, azithromycin, and preventive anticoagulation by enoxaparin sodium (0.8 mL \times two per 24 h subcutaneously). On October 23rd, 2020, the patient received dexamethasone 6 mg/day because of a persistent SpO₂ of 85% on room air and a fever (38.6 °C). After multiple desaturation episodes despite increased oxygen support (up to 6 L/min), he received a bolus of 120 mg methylprednisolone and was

There have been few studies on mixed mold diseases, and they are rarely reported in immunocompromised patients with neutropenia, malignant hemopathy [1,2], solid organ transplantation [3], or poorly controlled diabetes mellitus [4,5]. Viral infections, especially severe influenza and COVID-19, which cause acute respiratory distress syndrome (ARDS), increase the susceptibility to mold infection in previously immunocompetent patients [6,7]. COVID-19-associated pulmonary aspergillosis (CAPA) and COVID-19-associated mucormycosis (CAM) are associated with a higher mortality rate in this patient population [8,9]. CAPA and CAM prevalence rates vary widely between studies, which may be explained by different awareness and diagnostic strategies [8]. Our center screened every mechanically ventilated COVID-19 patient who clinically worsened despite adequate standard of care for CAPA. This case is a patient with *Rhizopus*/

* Corresponding author at: Hôpital Saint-Louis, Laboratoire de parasitology-mycologie, 1 avenue Claude Vellefaux, 75010 Paris.

E-mail address: sarah.delliere@aphp.fr (S. Dellière).

https://doi.org/10.1016/j.mycmed.2021.101231 1156-5233/© 2021 SFMM. Published by Elsevier Masson SAS. All rights reserved.

Fable	1	

Summary of mycological results.

	BAL Day 19	Serum Day 19	BAL Day 24	Plasma Day 24
DE	Negative	ND	Aspergillus- and Mucorales-type mycelium	ND
Culture	Aspergillus welwischiae Candida parapsilosis	ND	Rhizopus delemar Aspergillus welwischiae	ND
GM Ag	GM Ag > 4.63	GM Ag > 4.63	GM Ag > 5.12	ND
BDG	ND	30.7 pg/mL	ND	ND
PCR Mucor / Rhizopus	negative	positive* (Cq 30.87)	positive (Cq 25.65)	positive (Cq 24.62)
PCR A. fumigatus	negative	negative	negative	negative

BAL: Bronchoalveolar lavage ; BDG: Beta D glucan; Cq: Quantification cycle ; DE: Direct examination; GM Ag: Galactomannan Antigen; ND : Not done; PCR: Polymerase chain reaction; *PCR added retrospectively.

transferred to the intensive care unit (ICU) on October 26, 2020 (Day 1). The patient presented with polypnea (respiratory rate, 34 breaths/ minute) with signs of respiratory distress such as abdominal breathing and SpO₂ 91% under 15 L/min of oxygen. His-white blood cell count was 10,000 cells per mm³ (normal range, 4000 to 10,000) with 90% neutrophils (9040, normal range 1700 to 7000 cells per mm³) and 3.8% lymphocytes (400, normal range 1500 to 4500 cells per mm³), and his C-reactive protein level was 194 mg/dL (normal value <5 mg/dL), procalcitonin was 1.49 μ g/L (normal value <0.05 μ g/L), fibrinogen was 7.77 g/L (normal range 2 to 4 g/L), and D-dimer was 2830 ng/mL (normal value <500 ng/mL). He had metabolic alkalosis with profound hypoxemia at 55 mmHg and lactatemia at 1.4 mmol/L. The simplified acute physiology score II (SAPSII) and Sepsis-related Organ Failure Assessment (SOFA) at 24 h were 32 and 4, respectively. Ceftriaxone and azithromycin were discontinued on Day 2 after negative microbiological results from respiratory samples.

On Day 6, the patient's condition deteriorated due to acute heart failure. Mechanical ventilation was initiated. Dexamethasone was increased to 10 mg twice daily and piperacillin/tazobactam was empirically prescribed. The patient subsequently presented with multiple organ failure.

Bronchoalveolar lavage (BAL) was performed on Day 7 and identified 5×10^3 colony forming units (CFU)/mL of *Pseudomonas aeruginosa* that was resistant to piperacillin/tazobactam, and a chest CT angiography showed a bilateral segmental pulmonary embolism with p-dimer >3000 ng/mL. Ceftazidim and intravenous unfractionated heparin were introduced on Day10.

On Day 15, a second BAL identified ventilation-associated pneumonia with 10³ CFU/mL *P. aeruginosa*, 10⁴ CFU/mL *Stenotrophomonas maltophila*, and herpes simplex virus (HSV)–1 reactivation at 8 log copies/mL. He was administered cefepime, amikacin, and sulfamethoxazole–trimethoprim (800 mg twice daily). Acyclovir was introduced on Day 16 before HSV-1 and cytomegalovirus viremia (4.37 log copies/mL and 2.2 log IU/mL).

The evolution was initially favorable, but a new degradation with hemodynamic and acute renal failure on Day 19 required initiation of renal replacement therapy. A new CT-scan highlighted a right apical excavation with peripheral condensation, which was associated with overall stability in the areas with a ground glass appearance and an increase in bilateral subpleural condensation in the postero-inferior segments (Figure 2). BAL performed on Day 19 was positive for *Aspergillus* section *Nigri* and was associated with a positive BAL galactomannan index >4.63 (Platelia *Aspergillus* enzyme immunoassay, Biorad). The concomitant serum galactomannan index was also >4.63 (Table 1). Voriconazole was introduced on Day 19.

A third BAL was performed on Day 24 due to symptom persistence despite antifungal treatment. BAL results were positive for *Aspergillus* and Mucorales type mycelium upon direct examination, *Aspergillus* section *Nigri* and *Rhizopus* sp. grew in culture (Figure 2), and *Mucor/Rhizopus* qPCR results on BAL and serum samples were positive [9] (Cq value, 25.6 and 24.6, respectively). *Mucor/Rhizopus* qPCR performed retrospectively on the Day 19 sample was positive and showed a 2 log increase of the circulating fungal load in only 5 days

under voriconazole therapy (Cq from 30.8 to 24.6). *Aspergillus fumigatus*-specific PCR [10] was negative on all samples. Voriconazole was switched to liposomal amphotericin B on Day 25, but the patient died on Day 26.

We retrospectively studied the two strains that were identified. *Aspergillus* section *Nigri* was identified as *Aspergillus* welwitschiae by sequencing using calmodulin as a target with CL1/CL2a primers [11], and *Rhizopus* sp. was identified as *Rhizopus* delemar by sequencing with an internal transcribed spacer (ITS) as a target. *A.* welwischiae and *R.* delemar underwent antifungal susceptibility testing using the EUCAST method and showed minimal inhibitory concentrations (MICs), respectively, for posaconazole (0.5 mg/L and 0.5 mg/L), itraconazole (2 mg/L and 4 mg/L), voriconazole (1 mg/L and \geq 8 mg/L), isavuconazole (2 mg/L and 2 mg/L), amphotericin B (4 mg/L and 0.125 mg/L), micafungin (\leq 0.008 mg/L and \geq 4 mg/L), caspofungin (0.5 mg/L and \geq 4 mg/L).

In the ICU that cared for the patient, 153 patients were admitted for severe COVID-19 between March 2020 and February 2021, of whom 84 were mechanically ventilated. Among these latter patients, five (6.0%) developed CAPA and one (1%) developed a mixed mold infection, highlighting the rarity of this triple association. No other mucormycosis cases were reported.

LITERATURE REVIEW

References for this review were identified by searching the PubMed database using a combination of title keywords that referred to mixed mold infection (mucormycosis AND (aspergillosis OR aspergillus), mixed fungal infection, mixed mold infection). Thirty five cases reporting Aspergillus and Mucorales were analyzed (Table 2). These cases were described mostly in males (n = 21; 60%) with a median age of 51 (IQR, 34-65) years. These mixed infections were reported in patients with hematological malignancy (n = 12; 34%), diabetes (n = 10; 29%), trauma (n = 3; 9%), solid cancer (n = 1; 3%), solid organ transplantation (n = 1), Castleman disease (n = 1), and while receiving high-dose corticosteroids (n = 4). Most infections involved the lungs (n = 21; 60%) and CT scan showed cavitations (n = 13; 62%). Sinuses, brain, and skin were involved in 11 (31%), 4 (11%), and 2 (6%) cases, respectively. When identified to the Aspergillus species level (n = 22; 69%), A. fumigatus was isolated in 15 (69%) patients followed by A. flavus (n = 5; 23%), and A. niger (n = 3; 14%). In two cases, multiple Aspergillus species were isolated. Mucorales were rarely identified to the species. The most frequently identified genera were Mucor (n = 11; 31%) and Rhizopus (n = 8; 23%) followed by Lich*teimia* (n = 4; 11%), *Cunninghamella* (n = 3; 9%) and *Rhizomucor* (n = 2; 9.1%). In fifteen cases, Mucorales order members were only identified upon histopathological biopsy examination. In twelve (34%) cases, aspergillosis was diagnosed before mucormycosis and voriconazole was prescribed, and the patient was subsequently switched to amphotericin B. Thirteen of 35 (37%) patients died. Among these thirteen patients, most had European Organization for Research and Treatment of Cancer (EORTC) host factors (hematological malignancy, n = 5; high dose corticosteroids, n = 3; cancer under chemotherapy,

Table 2 Published cases of mixed mucormycosis and aspergillosis infection.

ω

Reference	Sex	Age	Underlying condition	Localization	Imaging	Aspergillus sp.	Mucorales sp.	Concomittant isolation	Classification*	Treatment	Outcome
Bellanger (2021) [15]	М	55	COVID-19; Neutropenia; Hematological malignancy	Lung	Not contributive	Aspergillus fumigatus	Rhizopus microsporus	YES	Probable°	AMB	Died
ohnson (2021) [16]	М	79	COVID-19; Diabetes	Lung	Cavitation	Aspergillus fumigatus	Rhizopus oryzae	Aspergillus first	Probable°	VCZ->AMB	NA
Bretagne (2021) [37]	М	73	COVID-19; Diabetes	Lung	Not contributive	Aspergillus fumigatus	Rhizopus microsporus	YES	Putative	AMB	Alive
Buil (2021) [38]	М	Late 50 s	COVID-19	Lung	Cavities, reversed halo-sign	Aspergillus fumigatus	Lichtheimia ramosa	Aspergillus first	Probable°	$VCZ \rightarrow AMB+PCZ$	Died
Buil (2021) [38]	М	Late 60 s	COVID-19, Hematological malignancy, Diabetes, Obesity	Lung	Progression of pulmonary lesions,dissemination to the kidneys	Aspergillus fumigatus	Rhizopus. microsporus	Aspergillus first	Proven	$VCZ+MCF \rightarrow ICZ \rightarrow AMB$	Died
Present case	М	74	COVID-19; High dose corticosteroids	Lung	Cavitation	Aspergillus niger	Rhizopus delemar	Aspergillus first	Probable°	VCZ->AMB	Died
Bergantim (2013) [39]	F	58	Hematological malignancy	Lung	Consolidation; Cavitation	Aspergillus sp.	Mucor sp.	YES	Proven*	AMB	Alive
Chermetz (2016) [40]	F	17	Cerebral glioma; Chemotherapy	Brain; Sinus	Sinus opacification; Brain lesion	Aspergillus flavus	Rhizomucor sp.	YES	Proven*	AMB	Died
Davoudi (2014) [2]	F	24	Hematological malignancy; Neutropenia	Lung	Opacities; Cavitation	Uncultured	Rhizomucor sp.	YES	Proven*	AMB+VCZ+CAS	Alive
Hu (2021) [41]	F	51	Hematological malignancy	Lung,	gastrointestinal	Massive high-density shadow in the right superior lobe, free abdominal gas under the diaphragm, and peritoneal fluid	Aspergillus flavus	Cunninghamella bertholletia	YES	Proven*	VCZ→ D-AMB →AMB→ Posaconazo
Alive Johnson (1993) [42]	F	38	Hematological malignancy;	Skin	NA	Aspergillus niger	Rhizopus oryzae	YES	Probable*	AMB	Died
Kishel (2008) [43]	F	49	HSCT Hematological malignancy;	Sinus	NA	Aspergillus sp.	Mucor sp.	YES	Probable*	AMB+CAS	Died
Lai (2021) [44]	М	70	Neutropenia COVID-19, High dose	Lung	Infiltrations	Aspergillus terreus	Cunninghamella	Aspergillus first	Probable°	$\text{VCZ+} \text{ADF} \rightarrow \text{AMB}$	Died
Leelawattanachai (2019) [45]	М	44	corticosteroids Trauma	Lung	Cavitation	Aspergillus fumigatus; Aspergillus flavus	bertholletiae Lichteimia corymbifera; Rhizopus microsporus	YES	Putative	AMB->PCZ	Alive
Lin (2019) [45]	М	52	Diabetes	Lung	Cavitation	Uncultured	Uncultured	Aspergillus first	Proven*	VCZ->AMB	Alive
Madan (2021) [47]	F	52 11	Beta thalassemia	Lung Sinus, eye	maxillary sinusitis,erosion of orbital bone,extension into right orbit	Aspergillus sp.	Mucor sp.	YES	Proven*	AMB→VCZ	Alive
Mahadevaiah (2013) [5]	F	27	Diabetes	Lung	Consolidation; Cavitation	Aspergillus fumigatus	Mucor sp.	YES	Proven*	AMB+VCZ	Died
Maiorono (2005) [48]	М	66	Castleman disease	Sinus	NA	Uncultured	Uncultured	YES	Proven*	AMB	Alive
Mantero (2019) [17]	F	55	High dose corticosteroids; Dermatomyositis	Brain	Abcess	Aspergillus sp.	Mucor sp.	Aspergillus first	Proven*	VCZ->AMB	Died
McLintock (2005) [1]	М	19	Hematological malignancy; Neutropenia	Lung	Cavitation	Aspergillus fumigatus	Lichteimia corymbifera	YES	Proven*	AMB+ITZ	NA
Moorthy (2021) [49]	M	45	COVID-19	Sinus, eye	NA	Uncultured	Uncultured	NM	Proven*	AMB	Alive
Obradovic-Tomasev (2014) [50]	М	28	Trauma	Skin	NA	Aspergillus sp.	Uncultured	Aspergillus first	Proven*	AMB+VCZ	Alive
Point (2017) [51]	М	61	Diabetes	Lung; Sinus	Consolidation; Sinus opacification	Aspergillus fumigatus	Uncultured	Aspergillus first	Proven*	VCZ->AMB	Alive
Pouvaret (2019) [52]	F	52	Hematological malignancy; Ibrutinib	Brain; Kidney	Abcess	Aspergillus fumigatus	Lichteimia sp.	Aspergillus first	Proven*	VCZ->AMB	Alive
Radowsky (2011) [53]	М	22	Trauma	Lung	NA	Aspergillus niger; Aspergil- lus terreus; Aspergillus flavus	Cunninghamella sp.	YES	Proven*	AMB	Died
Ravindra (2021) [54]	М	65	Alcoholic	Lung	Ground-glass opacity, consoli- dation (reverse halo sign), cavitating consolidation	Uncultured	Uncultured	YES	Proven*	AMB	Alive
Ravindra (2021) [54]	М	70	None	Lung	Intra-cavitary mass, crescent of air, thick-walled cavity	Aspergillus sp.	Mucor sp.	YES	Proven*	AMB	Alive
Safai Nodeh (2019)	F	34	Hematological malignancy; Neutropenia	Lung; Sinus	Sinus opacification; Bone lysis	Aspergillus sp.	Uncultured	Aspergillus first	Proven*	VCZ->AMB	Alive
[55]		72	COVID-19, Hematological	Lung, sinus	Pseudo-nodular cavitary, con-	Aspergillus fumigatus	Mucor circinelloides	Aspergillus first	Probable*	$VCZ+ADF \rightarrow AMB$	Died
[55] Saltini (2021) [56]	М		malignancy, Diabetes, High dose corticosteroids		solidations, inflammatory thickness of the left maxil- lary sinus					+CPF	

(continued on next page)

Singh (2021) [57] F 60 Diabetes			Imaging	Asperginus sp.	Mucorales sp.	Concomittant isolation	Classification* Treatment	Treatment	Outcome
Mangri (2011) [58] M 33 Ulaberes Winner (2012) [58] M 10 Hematoho	Diabetes Diabetes Hematological carlignanov	Rhino-ocular Sino-nasal	NA NA Disseminated	Aspergillus fumigatus Aspergillus fumigatus Cavitation	Mucor sp. Mucor sp. Asnoraillus fumicatus	YES YES Rhizomus so	Proven [*] Proven [*] Mucorales	AMB→ ITRA AMB→ VCZ Proven*	Alive Alive AMR
ž	טפרמו ווומווקוומוורץ.	'suns	הואכווווומרכת	Cavitation	cungurus Junugurus	.de endoznivi	first	1100011	
Zayet (2021) [4] F 69 Diabetes		Sinus; Eyes; Brain	Sinus opacification; Bone lysis	Aspergillus flavus	Uncultured	Mucorales first	Proven*	AMB	Alive
Zhan (2008) [3] M 41 SOT (kidne	SOT (kidney and liver)	Liver	NA	Aspergillus sp.	Mucor sp.	YES	Proven*	NA	Died
DF: Anidulafungin ; AMB: liposomal amphotericin B; CPF : caspofungin EORTC/MSG: HSCT: hematopoeitic stem cell transplant, ICZ: isavuconazole ; MCF: micafungin; NA: not assessed ; NM : not mentionned; PCZ: posaconazole; SOT: solid organ transplant; VCZ: voriconazole. Classification used was "ECMM/ISHAM for COVID-19 patients [7], "EORTC/MSGERC (European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Concorrium) ABIAF et al. 178(her et al. 198(her et al. 198(he	cin B; CPF : caspofung on used was °ECMM/I seive care unit with FG	gin EORTC/MSG: ISHAM for COVII	HSCT: hematopoeitic stem c D-19 patients [7], *EORTC/MS oct factor and proven infactiv	ell transplant, ICZ: isavu SGERC (European Organi anv switched to	conazole ; MCF: micafur zation for Research and	ngin; NA: not assesse Treatment of Cancer	d ; NM : not men and the Mycose	tionned; PCZ: pos is Study Group Ed	saconazole; SOT: solid lucation and Research

Fable 2 (Continued)

n = 1; solid organ transplantation, n = 1; diabetes, n = 1; COVID-19 only, n = 1; Trauma, n = 1). Nine mixed infections were reported in COVID-19 patients including our patient, and among these three patients, five had underlying risk factors (hematological malignancy and diabetes) and two received high-dose corticosteroids for COVID-19. Seven patients had lung infections. Overall, no specificities emerged from these cases compared to other patients with mixed *Aspergillus*/Mucorales infection.

Discussion

Here, we report the case of a patient with severe SARS-CoV-2 infection with the probable complications of CAPA and CAM.

One important aspect of our case is the co-infection with both *A. welwischiae* and *R. delemar. Aspergillus* and *Rhizopus* are two fungal genera with an angioinvasive ability. This association has been rarely described in the immunocompromised subject with an often fatal outcome in pulmonary and brain localizations (Table 2). More cases are described in case series of mucormycosis with up to 44.4% of *Aspergillus* co-infection [12]. Furthermore, the VITAL trial that assessed the efficacy of isavuconazole for treatment of mucormycosis also reported six cases among 37 patients, suggesting that this co-infection may be underdiagnosed [13,14]. The triple association COVID-19/*Aspergillus*/Mucorales has been reported in severely immunocompromised patient after stem cell transplantation and in patients with diabetes mellitus [15,16]. In one other case, a mixed mold infection was reported in a patient receiving high-dose cortico-steroids for dermatomyositis [17].

There have been several publications on the subject of COVID-19 and mold co-infection since the beginning of the first COVID-19 pandemic wave. The main co-infection that was studied was aspergillosis [7,18,19], and these studies highlighted several potential risk factors including intubation and mechanical ventilation, high-dose corticosteroids [20,21], azithromycin for \geq 3 days [22], tocilizumab [23,24], and immunological storm including high inflammatory cytokine levels [18]. CAM was reported less frequently especially in the first two COVID-19 pandemic waves, but it appears to be an increasing problem in India [25]. Although mucormycosis and mixed Aspergillus-Mucorales infection have been described less frequently, risk factors are expected to be similar [25,26]. Most cases of CAM are reported in patients with underlying conditions who are at a high risk of contracting these invasive infections (i.e. EORTC and the Mycoses Study Group Education and Research Consortium [EORTC/MSGERC] host factors or diabetes mellitus), and is it unclear whether COVID-19 infection is associated with a higher risk in this population or if there is a publication bias toward mucormycosis in patients with concomitant COVID-19 infection. Our patient was immunocompetent before contracting COVID-19. The risk factors for co-infection with mold disease were azithromycin administration for 7 days, high-dose corticosteroids, and the use of mechanical ventilation. This combination of factors probably led to the development of mixed invasive fungal disease.

Similar to any environmental mold that is isolated in respiratory specimens, there is always a discussion about colonization and infection. Because most COVID-19 patients have no classical host factors for invasive mold disease, other classifications besides the EORTC/ MSGERC classification [27] were developed and used to identify invasive fungal diseases. These classifications are AspICU [28], an influenza-associated pulmonary aspergillosis classification developed by Verweij et al. [29], and most recently, a classification that was proposed by ECMM/ISHAM [7]. Both aspergillosis and mucormycosis are consistent with putative or probable CAPA or CAM because both BAL direct examination and culture results were positive. Additionally, a CT-scan showed patterns that were compatible with invasive fungal disease. Furthermore, a highly positive galactomannan index in both blood and BAL and a positive Mucorales qPCR result in the blood




Fig. 1. Time course of the patient with COVID-19-associated pulmonary aspergillosis and COVID-19-associated mucormycosis. AMb, liposomal amphotericin b; AN, amikacin; ATB, antibiotic; ATF, antifungal; AZT, azithromycin; BAL, bronchoalveolar lavage; CTC, corticosteroids; CTX, cefotaxime; DXM, dexamethasone; FEP, cefepime; GM Ag, galactomannan antigen; ICU, intensive care unit; MP, methylprednisolone; PCR, polymerase chain reaction; SXT, sulfamethoxazole-trimethoprim: VORI voriconazole

strongly suggested an invasive disease. Therefore, the patient could have been classified as having a CAPA and CAM infection. However, careful investigation of our patient's corticosteroids doses indicated that he met the EORTC criteria [27] because he received a prednisone equivalent dose >0.3 mg/kg/day for 3 weeks (0.08 mg/kg/day of dexamethasone for 8 Days [0.6 mg/kg/day prednisone equivalent], 0.3 mg/kg/day of dexamethasone for 20 Days [1.9 mg/kg/day prednisone equivalent], and a methylprednisolone bolus of 120 mg [150 mg prednisone equivalent]) [27,30]. Therefore, a careful evaluation of the cumulative dose is required before concluding that the patient has no known EORTC/MSGERC risk factor for invasive mold infection.

Aspergillus section Nigri is also worth discussing because it is rarely responsible for infection compared to Aspergillus fumigatus due to its physiological characteristics such as its large conidia, which makes it more difficult to reach alveoli, and its optimal germination temperature, which is approximately 30 °C [31]. Invasive aspergillosis due to *A*. section *Nigri* is mostly reported in severely immunocompromised patients [32]. One other case report describes a fatal CAPA infection due to *A*. section *Nigri* with a high galactomannan index at Day 10 after ICU admission [33]. The delay between hospitalization in the ICU and CAPA infection of 19 days was longer than the median time that was published in CAPA cohorts of approximately 6 days [29]. This could be explained because reaching a critical dose of corticosteroids was required for invasive disease to develop in a previously immunocompetent patient.

Molecular biology tools to diagnose invasive fungal infections (IFIs) have only recently been developed. Aspergillus qPCR have been included in international guidelines for invasive aspergillosis since 2020 [27], and they are included when making a CAPA diagnosis [7]. However, detection of circulating Mucorales DNA (cmDNA) is not recommended by default to diagnose mucormycosis [34] despite data showing a high sensitivity and its ability to predict a diagnosis and quantify the fungal burden [9]. The important angioinvasive ability of Mucorales makes it possible to detect the fungus in blood samples. Regular screening of at-risk patients such as severely burned patients suggests that cmDNA detection allows an earlier diagnosis of invasive mucormycosis in this population and earlier treatment initiation [35]. Unlike galactomannan detection for the diagnosis of aspergillosis, there are no tools that target the Mucorales antigens, which emphasizes the need to include cmDNA detection in the mucormycosis diagnosis standards. This could be considered to be a screening tool for COVID-19 patients who are clinically worsening despite an appropriate standard of care and who have additional risk factors such as uncontrolled diabetes or high-dose corticosteroids.

Finally, there are no guidelines or standard practice for IFI management in COVID-19 patients, and clinical effectiveness of antifungal administration in these cases has not been demonstrated [7]. The treatment that is being promoted for patients with CAPA is intravenous voriconazole or isavuconazole, the latter of which covers the Mucorales species and *Aspergillus* species, and is showing promise in




Fig. 2. (A) Chest CT on day 19 after symptom onset, which shows a right apical excavation with peripheral condensation. Direct examination of the bronchoalveolar lavage with calcofluor white showing (B) *Aspergillus*-type mycelium (original magnification × 200) and (C) Mucorales-type mycelium (original magnification × 400). Microscopic culture examination with cotton blue showing (D) *Aspergillus niger* and (E) *Rhizopus delemar* (original magnification × 200).

mixed mold infections [7,14]. In 34.2% of co-infections that were analyzed in this literature review, *Aspergillus* was identified and treated first with voriconazole suggesting that the mucormycosis may be a breakthrough IFI that could be avoided using isavuconazole as a firstline treatment. Our patient was treated with voriconazole, against which *Rhizopus delemar* has high a MIC, which was confirmed by our data [36]. He was later switched to liposomal amphotericin B after Mucorales-type mycelium was identified in the direct BAL examination. However, this antifungal modification may have occurred too late in the infection's course considering that the serum PCR was retrospectively found to be positive 6 days before the antifungals were changed.

CONCLUSION

The SARS-CoV-2 virus has highlighted the existence of multiple fungal superinfections in patients who were not previously immunocompromised and who did not have common risk factors for invasive mold disease. However, the cumulative steroid dose for concomitant COVID-19 infection should be considered to be a risk factor for fungal infection in these patients. These superinfections, particularly CAPA and mucormycosis and the association between the two infections, as shown in the case of our patient, require adapting the management of these patients by screening respiratory and serum samples using biomarkers.

Declaration of Competing Interest

The authors have nothing to declare

Acknowledgment

We thank Dea Garcia-Hermoso, Cécile Gautier and Agathe Bertho from the French national reference center for invasive fungal diseases and antifungals for their expertise. We thank all staff, nurses and lab technicians who were essential to patient care in intensive care and medical mycology from Saint-Louis Hospital and Lariboisière Hospital.

References

- McLintock LA, Gibson BES, Jones BL. Mixed pulmonary fungal infection with Aspergillus fumigatus and Absidia corymbifera in a patient with relapsed acute myeloid leukaemia. Br J Haematol 2005;128:737. doi: 10.1111/j.1365-2141.2005.05379.x.
- [2] Davoudi S, Anderlini P, Fuller GN, Kontoyiannis DP. A long-term survivor of disseminated Aspergillus and mucorales infection: an instructive case. Mycopathologia 2014;178:465–70. doi: 10.1007/s11046-014-9785-x.
- [3] Zhan HX, Lv Y, Zhang Y, Liu C, Wang B, Jiang YY, et al. Hepatic and renal artery rupture due to Aspergillus and Mucor mixed infection after combined liver and kidney transplantation: a case report. Transplant. Proc. 2008;40:1771–3. doi: 10.1016/j.transproceed.2007.10.013.
- [4] Zayet S, Zaghdoudi A, Ammari L, Kilani B. Tiouiri Benaissa H. Cerebro-rhinoorbital mucormycosis and aspergillosis coinfection in a patient with diabetes mellitus: a case report. IDCases 2021;23:e01022. doi: 10.1016/j.idcr.2020.e01022.
- [5] Mahadevaiah AH, Rajagopalan N, Patil M, C S. Coinfection of pulmonary mucormycosis and aspergillosis presenting as bilateral vocal cord palsy. BMJ Case Rep 2013;2013:bcr2013009615. doi: 10.1136/bcr-2013-009615.
- [6] Schauwvlieghe AF, Rijnders BJ, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. The Lancet Respiratory 2018;6:782–92. doi: 10.1016/S2213-2600(18)30274-1.
- [7] Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis 2020. doi: 10.1016/S1473-3099(20)30847-1.
- [8] Prattes J, Wauters J, Giacobbe DR, Salmanton-García J, Maertens J, Bourgeois M, et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients— a multinational observational study by the European Confederation of Medical Mycology. Clin Microbiol Infect 2021:1–30. doi: 10.1016/j.cmi.2021.08.014.
- [9] Millon L, Herbrecht R, Grenouillet F, Morio F, Alanio A, Letscher-Bru V, et al. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in

serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). Clin Microbiol Infect 2016;22 810.e1–810.e8. doi: 10.1016/j.cmi.2015.12.006.

- [10] Alanio A, Menotti J, Gits-Muselli M, Hamane S, Denis B, Rafoux E, et al. Circulating aspergillus fumigatus DNA is quantitatively correlated to galactomannan in serum. Front Microbiol 2017;8:405–8. doi: 10.3389/fmicb.2017.02040.
- [11] O'Donnell K., Nirenberg H.I., Aoki T., Cigelnik E. Amultigene phylogeny of the Gibberella fujikuroi species complex: detection of additional phylogenetically distinct species. Mycoscience n.d.;41:61–78.
- [12] Saegeman V, Maertens J, Ectors N, Meersseman W, Lagrou K. Epidemiology of mucormycosis: review of 18 cases in a tertiary care hospital. Med Mycol 2010;48:245–54. doi: 10.1080/13693780903059477.
- [13] Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 2016;16:828–37. doi: 10.1016/ S1473-3099(16)00071-2.
- [14] Marty FM, Cornely OA, Mullane KM, Ostrosky-Zeichner L, Maher RM, Croos-Dabrera R, et al. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Mycoses 2018;61:485–97. doi: 10.1111/ myc.12777.
- [15] Bellanger AP, Navellou J-C, Lepiller Q, Brion A, Brunel A-S, Millon L, et al. Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. Infect Dis Now 2021. doi: 10.1016/j.idnow.2021.01.010.
- [16] Johnson AK, Ghazarian Z, Cendrowski KD, Persichino JG. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med Mycol Case Rep 2021;32:64– 7. doi: 10.1016/j.mmcr.2021.03.006.
- [17] Mantero V., Basilico P., Pozzetti U., Tonolo S., Rossi G., Spena G., et al. Concomitant cerebral aspergillosis and mucormycosis in an immunocompetent woman treated with corticosteroids 2019:1–4. doi:10.1007/s13365-019-00804-4.
- [18] Arastehfar A, Carvalho A, van de Veerdonk FL, Jenks JD, Koehler P, Krause R, et al. COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment. J Fungi 2020;6 91–17. doi: 10.3390/jof6020091.
- [19] Alanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. The Lancet Respiratory 2020;8:e48–9. doi: 10.1016/S2213-2600(20)30237-X.
- [20] White PL, Dhillon R, Cordey A, Hughes H, Faggian F, Soni S, et al. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa1298.
- [21] Bartoletti M, Pascale R, Cricca M, Rinaldi M, Maccaro A, Bussini L, et al. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa1065.
- [22] Dellière S, Dudoignon E, Fodil S, Voicu S, Collet M, Oillic P-A, et al. Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort. Clin Microbiol Infect 2020. doi: 10.1016/j.cmi.2020.12.005.
- [23] Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020;2:e474–84. doi: 10.1016/S2665-9913(20)30173-9.
- [24] Witting C, Quaggin-Smith J, Mylvaganam R, Peigh G, Angarone M, Flaherty JD. Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report. Diagn Microbiol Infect Dis 2021;99:115272. doi: 10.1016/j.diagmicrobio.2020.115272.
- [25] John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi 2021;7. doi: 10.3390/jof7040298.
- [26] Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, et al. A global analysis of mucormycosis in France: the RetroZygo study (2005-2007). Clin Infect Dis 2012;54:S35–43. doi: 10.1093/cid/cir880.
- [27] Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis 2020;71:1367– 76. doi: 10.1093/cid/ciz1008.
- [28] Blot SI, Taccone FS, Van den Abeele A-M, Bulpa P, Meersseman W, Brusselaers N, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med 2012;186:56–64. doi: 10.1164/ rccm.201111-19780C.
- [29] Verweij PE, Rijnders BJA, Brüggemann RJM, Azoulay E, Bassetti M, Blot S, et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med 2020;46:1524– 35. doi: 10.1007/s00134-020-06091-6.
- [30] Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. The Lancet 2003;362:1828–38. doi: 10.1016/S0140-6736(03)14904-5.
- [31] Gits-Muselli M, Hamane S, Verillaud B, Cherpin E, Denis B, Bondeelle L, et al. Different repartition of the cryptic species of black aspergilli according to the anatomical sites in human infections, in a French University hospital. Med Mycol 2021. doi: 10.1093/mmy/myab027.
- [32] Fianchi L, Picardi M, Cudillo L, Corvatta L, Mele L, Trapè G, et al. Aspergillus niger infection in patients with haematological diseases: a report of eight cases. Mycoses 2004;47:163–7. doi: 10.1111/j.1439-0507.2004.00960.x.
- [33] Trovato L, Calvo M, Migliorisi G, Astuto M, Oliveri F, Oliveri S. Fatal VAP-related pulmonary aspergillosis by Aspergillus niger in a positive COVID-19 patient. Respir Med Case Rep 2021;32:101367. doi: 10.1016/j.rmcr.2021.101367.
- [34] Cornely OA, PhD AA-I, PhD DA, PhD SCAC, MD ED, MD BH, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the

European confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis 2019;19:e405–21. doi: 10.1016/S1473-3099(19)30312-3.

- [35] Legrand M, Gits-Muselli M, Boutin L, Garcia-Hermoso D, Maurel V, Soussi S, et al. Detection of circulating mucorales DNA in critically ill burn patients: preliminary report of a screening strategy for early diagnosis and treatment. Clin Infect Dis 2016;63:1312–7. doi: 10.1093/cid/ciw563.
- [36] Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol 2008;46:567–73. doi: 10.1080/13693780801975576.
- [37] Bretagne S, Sitbon K, Botterel F, Dellière S, Letscher-Bru V, Chouaki T, et al. COVID-19-associated pulmonary aspergillosis, fungemia, and pneumocystosis in the intensive care unit: a retrospective multicenter observational cohort during the first french pandemic wave. Microbiol Spectr 2021:e0113821. doi: 10.1128/Spectrum.01138-21.
- [38] Buil JB, van Zanten ARH, Bentvelsen RG, Rijpstra TA, Goorhuis B, van der Voort S, et al. Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021. Eurosurveillance 2021;26:1–4. doi: 10.2807/1560-7917.ES.2021.26.23.2100510.
- [39] Bergantim R, Rios E, Trigo F, Guimarães JE. Invasive coinfection with Aspergillus and Mucor in a patient with acute myeloid leukemia. Clin Drug Investig 2013;33 (Suppl 1):S51–5. doi: 10.1007/s40261-012-0022-4.
- [40] Chermetz M, Gobbo M, Rupel K, Ottaviani G, Tirelli G, Bussani R, et al. Combined orofacial aspergillosis and mucormycosis: fatal complication of a recurrent paediatric glioma—case report and review of literature. Mycopathologia 2016;181:723–33. doi: 10.1007/s11046-016-0021-8.
- [41] Hu Z-M, Wang L-L, Zou L, Chen Z-J, Yi Y, Meng Q-B, et al. Coinfection pulmonary mucormycosis and aspergillosis with disseminated mucormycosis involving gastrointestinalin in an acute B-lymphoblastic leukemia patient. Brazilian Journal of Microbiology 2021:1–6. doi: 10.1007/s42770-021-00554-8.
- [42] Johnson AS, Ranson M, Scarffe JH, Morgenstern GR, Shaw AJ, Oppenheim BA. Cutaneous infection with Rhizopus oryzae and Aspergillus niger following bone marrow transplantation. Journal of Hospital Infection 1993;25:293–6. doi: 10.1016/0195-6701(93)90116-h.
- [43] Kishel JJ, Sivik J. Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up. J Oncol Pharm Pract 2008;14:189–93. doi: 10.1177/ 1078155208094123.
- [44] Lai C-C, Wu C-J, Lee Y-C, Liu W-L. COVID-19 associated with concomitant mucormycosis and aspergillosis. J Microbiol Immunol Infect 2021. doi: 10.1016/j. jmii.2021.09.001.
- [45] Leelawattanachai P, Montakantikul P, Nosoongnoen W, Chayakulkeeree M. Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis. Tcrm 2019;15:589–95. doi: 10.2147/TCRM.S203625.

- [46] Lin L, Xue D, Lin T-Y, Wu Y-X, Jiang Y-T, Chen L-M. Pulmonary aspergillosis, mucormycosis, and actinomycosis co-infection presenting as a cavitary lesion in a patient with diabetes. Chin Med J (Engl) 2019;132:2512–3. doi: 10.1097/ CM9.0000000000000468.
- [47] Madan S, Beri S, Chakravarti A, Jain R, Maheshwari R. Rhino-orbital mucormycosis and aspergillosis in a child with thalassemia major on deferoxamine therapy. The Official Scientific Journal of Delhi Ophthalmological Society 2021;31:83–6. doi: 10.7869/djo.634.
- [48] Maiorano E, Favia G, Capodiferro S, Montagna MT, Muzio Lo L. Combined mucormycosis and aspergillosis of the oro-sinonasal region in a patient affected by Castleman disease. Virchows Arch 2005;446:28–33. doi: 10.1007/s00428-004-1126x.
- [49] Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi KK, Kale PG, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids—an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg 2021;20:418–25. doi: 10.1007/s12663-021-01532-1.
- [50] Obradovic-Tomasev M, Popovic A, Vuckovic N, Jovanovic M. Case report mixed fungal infection (aspergillus, mucor, and candida) of severe hand injury. Case Rep Infect Dis 2014:1–4. doi: 10.1155/2014/954186.
- [51] Point S, Gabriel F, Bégueret H, Jougon J, Lanternier F, Grenouillet F, et al. Tumor shape pulmonary mucormycosis associated with sinonasal aspergillosis in a diabetic patient. Med Mycol Case Rep 2017;19:13–7. doi: 10.1016/j. mmcr.2017.08.001.
- [52] Pouvaret A, Guery R, Montillet M, Molina TJ, Duréault A, Bougnoux ME, et al. Concurrent cerebral aspergillosis and abdominal mucormycosis during ibrutinib therapy for chronic lymphocytic leukaemia. Clin Microbiol Infect 2019;25:771–3. doi: 10.1016/j.cmi.2019.01.016.
- [53] Radowsky JS, Strawn AA, Sherwood J, Braden A, Liston W. Invasive mucormycosis and aspergillosis in a healthy 22-year-old battle casualty: case report. Surg Infect (Larchmt) 2011;12:397–400. doi: 10.1089/sur.2010.065.
- [54] Ravindra C.M., Rajaram M., Madhusmita M., ChToi P., Sneha L. Pulmonary Aspergillus and Mucor Co-Infection: a report of two cases. Sultan Qaboos Univ Med J 2021. doi:10.18295/squmj.6.2021.096.
- [55] Safai Nodeh SR, Dehghan Manshadi SA, Jahanbin B, Khodaveisi S, Giasvand F, Seifi A, et al. Invasive fungal consecutive infections in a patient with acute myeloid leukaemia. Niger J Clin Pract 2019;22:582–4. doi: 10.4103/njcp.njcp_359_17.
- [56] Saltini P, Palomba E, Castelli V, Fava M, Alagna L, Biscarini S, et al. Mucormycosis in CAPA, a possible fungal super-infection. J Fungi 2021;7:708. doi: 10.3390/ jof7090708.
- [57] Singh A, Mohanty A, Jha S, Gupta P, Kaistha N. Concomitant mucormycosis with aspergillosis in patients with uncontrolled diabetes mellitus: a case series. J Clin Diagnostic Res 2021;15 DR01–3. doi: 10.7860/JCDR/2021/47912.14507.
- [58] Weng T-F, Ho M-W, Lin H-C, Lu M-Y, Peng C-T, Wu K-H. Successful treatment of disseminated mixed invasive fungal infection after hematopoietic stem cell transplantation for severe aplastic anemia. Pediatr Transplant 2012;16:E35–8. doi: 10.1111/j.1399-3046.2010.01406.x.